SCHEMBL21928090

SCHEMBL21928090

Cc1ccc2c(c1)c1c3n2CCN(Cc2ccccc2)[C@@H]3CCC1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.90
HTR1A P08908 2/20 0.77
HTR2A P28223 1/20 0.77
HTR7 P34969 1/20 0.77
HTR6 P50406 1/20 0.77
KDM4E B2RXH2 8/20 0.74
HSD17B10 Q99714 4/20 0.74
PAX8 Q06710 1/20 0.67
ALDH1A1 P00352 4/20 0.64
LMNA P02545 2/20 0.64
RAD52 P43351 2/20 0.64
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
TEAD4 Q15561 2/20 0.60
YAP1 P46937 1/20 0.60
GAA P10253 3/20 0.59
ALOX15 P16050 1/20 0.57
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
TEAD1 P28347 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24113921 1.00 MAPT (0.90) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL16433498 0.87 MAPT (0.86) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL15278242 0.87 HTR1A (1.00) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL4152125 0.86 HTR1A (0.76) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL4170361 0.86 MAPT (0.83) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL4164222 0.80 RAD52 (0.75) MAPTHTR1AKDM4EHSD17B10PAX8
SCHEMBL4152515 0.80 HTR1A (0.67) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL24113877 0.80 MAPT (0.66) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL10005901 0.79 MAPT (0.73) MAPTHTR1AHTR2AHTR7HTR6
SCHEMBL11982788 0.79 KDM4E (0.72) MAPTHTR1AKDM4EHSD17B10PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008327-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2021-05-18 US disclosed
US-20200131186-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008327-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole PIR, DRD5, DRD1 MAPT 2712/4885HTR1A 63/4885HTR2A 379/4885
US-20200131186-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES PIR, CYP3A5, DRD5 MAPT 2680/4885HTR1A 134/4885HTR2A 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.